Isis Drug for Crohn’s Fails in Late-Stage Trials
From Bloomberg News
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn’s disease in two late-stage trials.
The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies.
Isis shares rose $1.09 to $6.01 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
